Inactief instrument

Andere talen Inovio Pharmaceuticals Inc Nyse

Aandelen

US45773H1023

slotkoers Nyse Andere beurzen
- ^USD	-

06/03	Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024
06/03	Inovio Pharmaceuticals, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

INOVIO Reports Inducement Grants Under Inducement Plan	01/05
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024	29/04
INOVIO to Participate in Upcoming Investor Conferences in May	29/04
Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	16/04
Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	16/04
Top Premarket Decliners	16/04
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	16/04
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine	26/03
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	07/03
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024	21/02
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
INOVIO Reports Inducement Grant Under Inducement Plan	02/02
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split	23/01
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader	22/01
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment	04/01
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)	04/01
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment	03/01
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	03/01
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Inovio Pharmaceuticals Inc Nyse

Aandelen

US45773H1023

Andere talen

Filters